• 1. Department of Thyroid Surgery, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, 610041, P. R. China;
  • 2. School of Medicine, University of Electronic Science and Technology of China, Chengdu 610056, P. R. China;
YANG Xianwei, Email: yxwdocor@163.com
Export PDF Favorites Scan Get Citation

Objective  To summarize the research status of echinococcosis- specific vaccine antigens, analyze their sources and application prospects, and to provide new ideas for the development of echinococcosis vaccine antigens and drug treatment. Method  Research on echinococcosis-specific vaccine antigens at home and abroad was searched and reviewed. Results  Natural hydatid antigens, such as cystic fluid crude antigen, protoscolex segment, germinal layer, etc. often appear due to the difficulty of material acquisition and cumbersome preparation, resulting in unstable evaluation indicators such as sensitivity and specificity. The gene or protein sequences of a new recombinant hydatid antigen was accessible, the reproducibility and specificity were better, and it was more suitable for batch production testing, which was the main direction of current research, such as rAgB8/1, rEm18, rEm2, etc. Conclusions  Vaccine development is one of the main directions for the elimination of hydatidosis. In the interaction between echinococcus and human or animal hosts, the natural structural proteins or excretion/secretion proteins of echinococcus stimulate the host to produce anti-parasites immunity and immune clearance, and the search for these specific protein antigens is of great significance for vaccine development, and new drug treatment.

Citation: YANG Xianwei, TAO Lang, WEI Jinwen, LIU Jinxian. Research status and prospect of echinococcosis-specific vaccine antigens. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2023, 30(6): 734-738. doi: 10.7507/1007-9424.202212066 Copy

  • Previous Article

    甲状腺内甲状舌管囊肿误诊为甲状腺腺瘤1例报道
  • Next Article

    Application progress of patient-derived organoid and patient-derived tumor xenograft